COMPASS Pathways announces changes in Executive Team
December 16, 2021 07:40 ET
|
COMPASS Pathways
Matthew Owens appointed General Counsel and Chief Legal Officer; Lars Wilde, Chief Business Officer and Co-founder, to move into senior advisory role London, UK – 16 December...
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
December 13, 2021 07:00 ET
|
COMPASS Pathways
Patients taking COMP360 psilocybin with concomitant SSRIs showed comparable treatment outcomes to patients withdrawn from their SSRI therapy in COMPASS’s phase IIb trialAll patients tolerated COMP360...
Michael Falvey joins COMPASS Pathways as Chief Financial Officer
December 03, 2021 07:00 ET
|
COMPASS Pathways
London, UK - 3 December 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
December 01, 2021 07:00 ET
|
COMPASS Pathways
- Positive topline results validated by additional analyses - Patient improvements beyond reduction of depression symptoms - Further insights into timing and circumstance of adverse...
COMPASS Pathways granted fifth US patent for crystalline psilocybin
November 23, 2021 07:00 ET
|
COMPASS Pathways
London, UK - 23 November 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
November 09, 2021 07:00 ET
|
COMPASS Pathways
Largest randomised, controlled, double-blind psilocybin therapy study ever completedshows rapid and sustained response for patients receiving a single dose of COMP360 psilocybin with psychological...
COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder
November 03, 2021 08:00 ET
|
COMPASS Pathways
London, UK – 3 November 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups
October 20, 2021 09:00 ET
|
COMPASS Pathways
Investigator-initiated study shows remission in major depression symptoms for 50% of participants London, UK – 20 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health...
COMPASS Pathways is granted new US patent for crystalline psilocybin
October 19, 2021 07:00 ET
|
COMPASS Pathways
London, UK – 19 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds
September 10, 2021 07:00 ET
|
COMPASS Pathfinder Ltd.
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has engaged Hamilton Morris,...